In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Iovance Biotherapeutics Inc (IOVA). The company’s shares closed yesterday at $11.01.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.8% and a 41.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Molecular Templates Inc, and CytomX Therapeutics Inc.
Currently, the analyst consensus on Iovance Biotherapeutics Inc is a Strong Buy with an average price target of $22.75, representing a 106.6% upside. In a report issued on April 29, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $20 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.25 and a one-year low of $7.26. Currently, Iovance Biotherapeutics Inc has an average volume of 1.03M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors.
